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5-Fluorouracil (5-FU) is a chemotherapeutic drug commonly used for the treatment of solid
cancers. It is proposed that 5-FU interferes with nucleotide synthesis and incorporates into
DNA, which may have a mutational impact on both surviving tumor and healthy cells. Here,
we treat intestinal organoids with 5-FU and ﬁnd a highly characteristic mutational pattern
that is dominated by T>G substitutions in a CTT context. Tumor whole genome sequencing
data conﬁrms that this signature is also identiﬁed in vivo in colorectal and breast cancer
patients who have received 5-FU treatment. Taken together, our results demonstrate that 5-
FU is mutagenic and may drive tumor evolution and increase the risk of secondary malig-
nancies. Furthermore, the identiﬁed signature shows a strong resemblance to COSMIC sig-
nature 17, the hallmark signature of treatment-naive esophageal and gastric tumors, which
indicates that distinct endogenous and exogenous triggers can converge onto highly similar
mutational signatures.
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The use of 5-Fluorouracil (5-FU) as an anticancer agentbecame routine practice soon after its primary synthesis in1957, and remains essential in many chemotherapeutic
regimens today1. The ﬂuoropyrimidines, especially 5-FU, cape-
citabine, tegafur, and cytarabine, are currently the third most
commonly used anticancer drug in the treatment of solid cancers,
including colorectal and breast cancers, and over two million
patients are estimated to be treated with ﬂuoropyrimidines each
year2. Response rates of 5-FU as a single drug are 10–15%, but
increase drastically (>50% response) when given in combination
therapies with leucovorin together with oxaliplatin or irinotecan
(i.e., FOLFOX and FOLFIRI, respectively)3–5.
The antifolate property of ﬂuoropyrimidines is thought to be
the principal mechanism of action. Fluoropyrimidines are intra-
cellularly converted into the antifolate 5-ﬂuorodeoxyuridine
monophosphate (5-FdUMP) that can form a covalent inter-
mediate with the folate-dependent enzyme thymidylate synthase
(TYMS)6 Consequently, the formation of dTMP from dUMP is
inhibited which results in an imbalance of the nucleotide pool
that affects DNA synthesis, possibly through incorporation of
uracil, and impairs genome replication, with negative con-
sequences for rapidly dividing cells such as cancer cells. More-
over, it has been proposed that 5-ﬂuorodeoxyuridine triphosphate
(5-FdUTP) can be directly incorporated into genomic DNA as
well7,8. Considering these properties, it is conceivable that
ﬂuoropyrimidines have mutagenic potential, although the muta-
tional consequences of 5-FU treatments are still poorly
understood.
In cancer, systematic analysis of genome-wide mutation cata-
logs has revealed a number of characteristic mutational patterns
or mutational signatures9. Some of these signatures have been
linked to perturbed endogenous processes like deﬁcient DNA
repair, or exogenous challenges, like exposure to UV-light or
mutagenic chemicals. Such information thus provides insight into
the mutational processes that have been active during tumor-
igenesis and which could potentially be used for prevention
strategies or personalized treatment strategies. Previously, it has
been shown that certain anticancer treatments can be associated
with characteristic mutational signatures, such as alkylating
agents9,10, cisplatin11,12 and ionizing radiation13,14. Unlike these
anticancer treatments, and in spite of its mutagenic potential, 5-
FU could thus far not be linked to any mutational signature using
these systematic cancer cohort analyses.
Here, we assess the mutational consequences of ﬂuoropyr-
imidines by exposing organoids of healthy intestinal stem cells to
5-FU followed by genome-wide analysis of single cells. For this,
we use a previously described highly sensitive approach based on
clonal expansion of individual cells followed by whole genome
sequencing (WGS) for mutational spectrum analysis15,16. In vitro
ﬁndings are subsequently validated by exploration of mutational
patterns in breast and colorectal cancer patients who have had
previous ﬂuoropyrimidine treatments. Our results demonstrate
that 5-FU induces both in vitro in organoids and in vivo in cancer
cells a similar mutational pattern that is reminiscent of COSMIC
signature 17.
Results
Characterization of 5-FU mutational effect in vitro. We have
set up human small intestinal (SI) isogenic organoid cultures
which were exposed to 5-FU for 3 days followed by 4 days of
recovery (Fig. 1a). This treatment procedure was repeated 5 times,
which allowed the organoids to survive the exposure conditions
and to accumulate a sufﬁcient number of mutations. Then,
individual organoid cells from the 5-FU exposed cultures were
manually picked, expanded and analyzed by WGS with a read
coverage-depth of ~30×. Somatic mutations were called against
the original isogenic organoid line which was also sequenced at
~30×. Lastly, mutations which arose after the single-cell-step were
ﬁltered out based on low variant allele frequencies (Supplemen-
tary Fig. 1). A total of 1324 highly conﬁdent induced single base
substitutions (SBSs) were identiﬁed in the autosomal genome that
were accumulated during 5-FU treatment (n= 2 organoid lines).
Organoids grown in parallel, but not exposed to 5-FU, served as
control (n= 6 organoid lines). Not unexpectedly, untreated
control organoids were found to proliferate faster than treated
organoids, which makes it impossible to accurately determine the
mutation accumulation load per cell division, although qualitative
aspects and relative mutation contributions can still be
interpreted.
To dissect active mutational processes, we analyzed the 96
mutational spectra of the obtained SBSs with trinucleotide
context in more detail. We observed a distinct mutation proﬁle
for 5-FU exposed organoids when compared to the background
in vitro mutation spectrum of untreated control SI organoids
(Pearson correlation= 0.26; cosine sim= 0.57) (Fig. 1b). The
most striking differences are the T > G mutations in a CTT
trinucleotide context (further referred as C[T>G]T mutations)
and, to a lesser extent, C[T>C]T and G[T>G]T mutations, which
together account for more than half of the total mutation proﬁle
of 5-FU-treated organoids. This illustrates that 5-FU induces a
characteristic mutational pattern in vitro that is driven by a
mutational process that generates SBSs with a chance of ~35%
being a CTT>CGT mutation.
5-FU-induced mutational pattern in human cancer. To assess if
the observed 5-FU mutational consequences can also be detected
in vivo in human cancer samples, we explored cancer whole-
genome sequencing data from metastatic cancer patients (Hart-
wig Medical Foundation database) for which treatment data is
also available17. 65% of colorectal (n= 352) and 36% of the breast
(n= 450) cancer patients in this data set underwent 5-FU based
treatment (i.e., 5-ﬂuorouracil, ﬂuoropyrimidine, capecitabine or
tegafur—further referred to as 5-FU) at any time prior to biopsy
and WGS. We performed an unbiased de novo mutational sig-
nature analysis using non-negative matrix factorization (NMF)18
on both cohorts with inclusion of the 5-FU exposed organoid
data. NMF identiﬁed sixteen mutational signatures which
all showed high similarity with well-described signatures in
human cancer (Fig. 2a, Supplementary Table 1) (http://cancer.
sanger.ac.uk/cosmic/signatures)19–21. Interestingly, a signature
that was highly similar to the 5-FU in vitro mutation spectrum
was found in the set of the de novo extracted signatures (Pearson
correlation= 0.98; cosine sim= 0.98) (Fig. 2a). This signature,
further referred as “5-FU signature” (Fig. 2b), is predominated by
C[T>G]T mutations (36%) which is almost equal to the 5-FU
in vitro mutation spectrum (35% of C[T > G]T mutations).
Ranking by the total mutational load of this 5-FU signature
illustrates that patients who display a prominent contribution of
this pattern were treated with 5-FU (Supplementary Fig. 2). These
results indicate that 5-FU has the same mutagenic effect in vivo as
in vitro.
5-FU signature contribution in human cancer. To quantify the
mutational contribution of the 5-FU signature we compared 5-FU
pretreated and non-5-FU pretreated patients (including a
treatment-naive primary colorectal22 and breast cancer cohort23
as additional controls). The relative contribution of the 5-FU
signature was calculated and compared for each patient to adjust
for differences in tumor mutational burden (TMB—number of
SBSs per Mbp) between primary and metastatic cohort24. In line
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with our previous results, 5-FU pretreated patients showed a
signiﬁcantly higher 5-FU signature contribution compared to 5-
FU untreated patients in both the colon and breast cancer cohort
(both P < 0.05, Wilcoxon rank-sum test) (Fig. 2c). No signiﬁcant
differences were found between the 5-FU untreated patients and
the treatment-naive cohorts. Examining the absolute mutational
contribution for all extracted signatures shows that only the 5-FU
signature is increased in contribution illustrating that 5-FU does
not have a measurable impact on other signatures (P < 0.05,
Wilcoxon rank-sum test, Supplementary Fig. 3). While 5-FU is
most commonly used to treat breast and colon cancer patients, it
is often also administered to patients with more rare cancer
indications including pancreas (n= 11), biliary tract (n= 6) and
head and neck (n= 5). In these cancer types, we identiﬁed the
same 5-FU mutagenic effect as in breast and colon cancer,
although not signiﬁcant due to the low number of patients, which
demonstrates that the 5-FU mutational process is tissue inde-
pendent (Supplementary Fig. 4).
We observed an extensive variation in the number of 5-FU
mutations per 5-FU treated patient ranging from 0 to roughly
15,000 mutations in both colon and breast cancer patients
(Supplementary Fig. 2). This may be explained by variation in
pharmacodynamics between patients, differences in the dosing
and the duration of 5-FU treatment schedules25, as well as by the
evolution dynamics, but potentially also by other characteristics
of the tumor. Indeed, analysis of tumor driver and suppressor
genes (n= 378) uncovered that TP53 mutated cancers accumu-
lated more 5-FU mutations than TP53 wild type cancers, both in
colon and breast (P < 0.05, Wilcoxon rank-sum test, Fig. 2d).
Also, ﬂuorouracil and capecitabine were both found to be
mutagenic in colon cancer, while in breast cancer only
capecitabine showed an increased mutagenic effect (Supplemen-
tary Fig. 5), which might reﬂect differences between both tissues
in drug uptake and treatment schemes. Notwithstanding the high
variation in 5-FU signature contributions between patients, we
observed that colon cancers overall have a higher 5-FU signature
contribution than breast cancers, with a median mutation count
of 1180 and 139 mutations, respectively.
The underlying clonal architecture of mutational events can be
inferred from the variant allele frequency (VAF) and provides
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Fig. 1 5-FU induces context dependent T>G mutations in vitro. a Schematic overview of the experimental setup used to determine the 5-FU mutation
spectrum in two independent human small intestinal organoid experiments. 6.25 μM 5-FU was added to isogenic organoids for 3 days, followed by a 4-day
rest period. This cycle was repeated 5 times. Subsequently, organoids were made single cell and expanded further into clonal organoids to obtain sufﬁcient
DNA for WGS. Controls were cultured in 5-FU-free medium. The WGS data of the original isogenic organoid line served as reference sample. b The
experimentally derived mutation spectra from 5-FU treated organoid lines (upper) and untreated organoid lines (middle). Each spectrum shows the
mutation probability of each indicated context-dependent base substitution type. The spectrum below shows the difference between the 5-FU (positive
values) and the in vitro (negative values) mutation spectrum
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Fig. 2 5-FU mutational pattern and its contribution in human cancer. a Heatmap showing the cosine similarity scores for each de novo extracted signature
with the in vitro experimental obtained 5-FU mutation spectrum. NMF H resembles the 5-FU experimental mutation spectrum (cos sim= 0.98) and is
further assigned as the “5-FU signature” in the main text. b 5-FU mutation signature showing the mutation type probability for each context-dependent
base substitution type. c Box-and whisker plots indicating the relative contribution of the 5-FU signature between 5-FU pretreated and not 5-FU pretreated
colon (left) and breast (right) cancer patients with inclusion of the treatment naive cancer cohort. d Box-and whisker plots showing the tumor mutational
burden (number of SBSs per Mbp) between 5-FU pretreated and not 5-FU pretreated cancer patients for the colon (left) and breast (right) cancer patients.
e Box-and whisker plots showing the 5-FU mutational load between TP53-wild type and TP53-mutant cancers in 5-FU pretreated colon (left) and breast
(right) patients. For all plots, a Wilcoxon rank-sum test between every cohort was performed and the P-value is illustrated at the top of the plots. All box-
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more insight into the timing of the activity of speciﬁc mutational
processes. In comparison to clonal mutations, we found
approximately a three-fold increase in the relative mutational
contribution of the 5-FU signature for the subclonal mutations
(P < 0.05, Wilcoxon rank-sum test, Supplementary Fig. 6). This
points out that the 5-FU induced mutagenic activity is more
profound in the metastatic colonies and therefore occurred at a
later stage in tumor development, which is in line with the time of
cancer diagnosis and subsequent 5-FU treatment.
5-FU mutations in paired biopsies. In the studied metastatic
cancer patient cohort, 53 patients underwent two or more serial
biopsies, which can be used to provide a more direct approach to
study the chronological timing of the activity of mutational
processes. This group of patients with multiple biopsies consisted
of different cancer types of which 8 patients (colorectal cancer
(n= 4) and breast cancer (n= 4)) that received a systemic 5-FU
related treatment after the ﬁrst biopsy and before one of the
following biopsies. For every patient, we determined the mutation
proﬁles of both biopsies and examined the difference in mutation
numbers for each of the 96 mutation types, reasoning that 5-FU
characteristic mutation types—particularly C[T>G]T mutations
—would increase in mutational load. A mixed-effect regression
analysis indeed revealed a positive correlation between the nor-
malized absolute count of C[T>G]T mutations from the ﬁrst
biopsy compared to the second biopsy in patients treated with 5-
FU (ANOVA linear mixed model; P < 0.05) (Fig. 3). Moreover,
iterating this statistical analysis on each of the 96 possible
mutation types resulted in signiﬁcant P-values for all mutation
types that are dominating the previously identiﬁed 5-FU sig-
nature (Fig. 3). Of note, no correlations were found between 5-FU
characteristic mutation types and any other administered treat-
ment drug (Carboplatin, Cisplatin, Oxaliplatin, Pazopanib,
Pembrolizumab, and Pemetrexed) demonstrating that the sig-
nature is highly speciﬁcally induced by 5-FU (Supplementary
Fig. 7).
5-FU signature resembles COSMIC signature 17. We compared
the obtained 5-FU signature to the known COSMIC signatures
and found a high similarity (Pearson correlation= 0.97; cosine
sim= 0.97) with COSMIC signature 17 (Fig. 4a), which is pre-
dominantly found in treatment-naive esophagus and gastric
cancer. Recent work has split COSMIC signature 17 into two
constituent signatures (SBS17a, predominantly characterized by
T>C mutations and SBS17b, characterized by T>G mutations)19,
suggesting two distinct mutational processes. However, the here
obtained 5-FU in vitro mutation spectrum showed both T>C and
T>G mutations as in COSMIC signature 17, and thus our ﬁnd-
ings provide no evidence that COSMIC signature 17 exhibit a
pattern of two independent mutational processes.
Next, we investigated whether the 5-FU signature also
encompasses more detailed molecular features that are character-
istic for COSMIC signature 17. In agreement with COSMIC sig-
nature 1726,27, we also found a seven-base mutation context for C
[T > G]T mutations in 5-FU pretreated colon and breast cancer
patients which is predominated by A/T bases at the −4, −3 and
−2 positions from the mutated base position (Fig. 4c). Further-
more, COSMIC signature 17 has been shown to display a higher
mutation rate on the lagging strand28,29. Consistent with these
reports, we observed a strong replication strand bias towards the
lagging strand for C[T>G]T mutations types in 5-FU pretreated
colon and breast cancer samples (Fig. 4b). In addition, we also
noted a minor transcriptional strand bias in the colon samples for
C[T>G]T mutations (Supplementary Fig. 8). Given this strong
overlap in characteristics between both signatures, we conclude
that the identiﬁed 5-FU signature is the same as COSMIC
signature 17 and does not represent a novel signature.
Impact on tumorigenesis. We observed an average increase
(~20%) in the overall TMB for 5-FU treated cancers, at least for
the colon cancer patients (P < 0.05, Wilcoxon rank-sum test)
(Fig. 2e). However, the 5-FU contribution on the TMB differs
extensively per patient (Supplementary Fig. 9) where most 5-FU
pretreated cancer patients (65% and 85% for colon and breast,
respectively) show a limited impact of 5-FU on the TMB (<10%)
and only a few patients (6% and 3% for colon and breast,
respectively) demonstrate a substantial 5-FU contribution that
affect the TMB with at least 30%. To investigate the impact of
these 5-FU mutations on tumor evolution and disease progres-
sion, we selected all subclonal synonymous and non-synonymous
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Note that most of the mutation types that characterize COSMIC signature 17 show a signiﬁcant increase in normalized mutation count for patients treated
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mutations that were most likely induced by 5-FU exposure for
each patient (see Methods) to quantify oncogenic driver muta-
tions induced by 5-FU (Supplementary Fig. 10). We observed no
increase in the number of validated oncogenic drivers30 in the 5-
FU pretreated colon (5 driver mutations) and breast (5 driver
mutations) cancer patients compared to non 5-FU pretreated
colon (2 driver mutations, P= 0.56, Fisher exact test) and breast
(5 driver mutations, P= 0.26, Fisher exact test) cancer patients
(Supplementary Table 2).
In an attempt to characterize genes that may have contributed
to 5-FU resistance, we performed a dN/dS analysis in which all
single-nucleotide mutations and small insertions and deletions
(INDELS) were included, but revealed no signiﬁcantly mutated
genes in contrast to resistance to hormonal therapies (e.g., ESR1
for breast and AR for prostate17,31) and targeted treatments (e.g.,
secondary BRAF mutations for melanoma treated with vemur-
afenib32 and secondary EGFR mutations treated with EGFR
inhibitors33).
Next, we investigated loss-of-function (LOF) and gain-of-
function (GOF) events of key enzymes of the pyrimidine
metabolic pathways. TYMS is considered as the key therapeutic
target for 5-FU and overexpression of its gene has been linked to
5-FU resistance in in vitro as well as in in vivo experiments34,35.
TYMS showed no LOF mutations in the breast and colorectal
cohort, supporting the ﬁndings that TYMS is an essential gene36.
On the other hand, GOF events of TYMS by means of copy
number gains were found in 5-FU pretreated colon cancer
patients (n= 44 out of 231) vs. untreated patients (n= 8 out of
121) (P < 0.05, Fisher exact test) (Supplementary Fig. 11),
although this was not observed for breast cancer patients. This
indicates a selective pressure towards increased levels of TYMS
activity after 5-FU administration. The copy number level of
TYMS seems to be inversely correlated with the absolute
contribution of 5-FU pattern (Supplementary Fig. 11), which
may suggest that TYMS overexpression can block the 5-FU
mutational process by overcoming binding of 5-FdUMP by sheer
number of TYMS protein.
It is interesting to note that, as we have shown with the
organoid experiments, normal cells also accumulate 5-FU
mutations. Consequently, it can be postulated that not only
cancer cells, but any other cell in the body exposed to 5-FU may
accumulate mutations that lead to the onset of secondary
malignancies. To quantify this risk, we modeled the chance of
introducing a cancer driver mutation resulting from 5-FU
treatment, using the 5-FU speciﬁc mutation context and in vivo
observed average mutation rate (Supplementary Fig. 12). This
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Fig. 4 Comparison between the 5-FU signature and COSMIC Signature 17. a Heatmap showing the cosine similarity scores for the in vitro 5-FU mutation
spectrum and the in vivo obtained 5-FU signature with the COSMIC signatures. Both patterns show a strong resemblance with COSMIC Signature 17.
b Replication strand bias of C[N>N]T mutations in 5-FU pretreated colon and breast samples and not 5-FU pretreated esophagus samples. Relative levels
of each base substitution type in the left (leading) and right (lagging) DNA strands are shown for each cohort. Asterisks indicate a signiﬁcant difference
(P < 0.05, two-sided Poisson test). c The eleven-base signature context of C[T>G]T mutations are presented as Logo plots. The mutated T is centered in
each plot with ﬁxed positions left (5’ direction) and right (3’ direction) from the mutation position
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model estimates that about 300 oncogenic mutations are
introduced in vivo in 108 colon stem cells per 5-FU treatment,
which is 50-fold higher than under normal conditions as a result
of in vivo mutational processes associated with aging. One full
cycle of 5-FU treatment, therefore, reﬂects ‘normal’ mutation
accumulation in colon stem cells of about 20 years16. As such, the
consequences of 5-FU administration may be limited for patients
with age above 60–70 years, but can be signiﬁcant for cancer
patients at a relatively young age (20–30 years old). Furthermore,
patients carrying germline predisposition variants (e.g., APC
mutation in FAP syndrome resulting in the development of
tumors at a relatively young age) are at increased risk for
acquiring a second hit and may be a contraindication for 5-FU
treatment. We modeled this scenario as well and found a 20-fold
increase in risk as compared to non-treated patients, which is
equivalent to reducing the average age of onset for tumor
development in FAP patients with 10 years.
Discussion
Here, we demonstrate a causal relationship between 5-FU treat-
ment and COSMIC signature 17, characterized by C[T > G]T base
substitutions.
This ﬁnding differs from a previous study that did not ﬁnd a
measurable mutagenic effect of 5-FU exposure in cultured
chicken lymphoblasts37. This discrepancy might be due to dif-
ferences in experimental conditions (5-FU dosage, mutation
detection) or the in vitro models used. Indeed, non-human cell
lines are known to differ in DNA damage susceptibility38, e.g.
exposing aﬂatoxin to cell lines, mouse tumors and human tumors
results in great diversity in mutation proﬁles39. Likewise, cisplatin
signatures characterized with cell lines of different model
organisms12,37 do not recapitulate the cisplatin patterns recently
found in human cancer11,19.
Since 5-FU is structurally similar to thymidine and uracil
nucleotides and has previously been shown to interfere with
nucleotide biosynthesis and nucleotide pools40–42, a mutagenic
effect of 5-FU was anticipated. However, the strong resemblance
with a previously described signature that was already linked to a
different potentially underlying mechanism was surprising.
COSMIC signature 17 is the hallmark signature of esophageal and
gastric cancers and the presence of gastric reﬂuxate has been
suggested to be the responsible mutagen in these cancer types.
High COSMIC signature 17 contributions are occasionally found
in non-5-FU treated patients diagnosed with other cancer types as
well9,23. For instance, a comprehensive study dissected the
intratumor heterogeneity of three treatment naive colorectal
tumors, of which one displayed extensive signature 17 contribu-
tion43. Thus, signature 17 reﬂects the consequences of a muta-
tional process that can be instigated by multiple triggers including
5-FU exposure.
Recent work has proposed that COSMIC signature 17 reﬂects
the mutagenic consequences of the presence of oxidized dGTP
nucleotides in the nucleotide pool29. Indeed, a number of studies
have reported that the presence of oxidized guanine nucleotides
(8-oxo-dGTP) increases the T>G mutation rate44,45. Accordingly,
inhibition of enzymes responsible for the removal of oxidized
nucleotides, such as MTH1, MTH2, and NUDT5, have been
shown to promote T>G mutations as well46. Also, the ﬂanking
sequence context of the dominant mutation type of Signature 17
mirrors the context of the dominant mutation type of Signature
18. This mutational process has been linked to direct oxidation of
guanine located inside the DNA47,48. It is, therefore, tempting to
speculate that the oxidation of dGTPs in the nucleotide pool
underlies COSMIC Signature 17. As such, the presence of bile
reﬂuxate would be a plausible explanation for the elevated levels
of 8-oxo-dGTP in esophagus cancer49. However, a recent study
showed that bile reﬂuxate alone does not generate 8-oxo-dGTPs,
but that bile acid also requires an acidic environment to promote
the production of 8-oxo-dGTP. This was only found in the epi-
thelial cells of premalignant Barrett’s esophageal cells, which
gained transporters for bile acids, potentially clarifying why
healthy esophageal cells do not show Signature 17 mutations49–51.
Based on this, one could hypothesize that 5-FU exposure induces
a similar oxidative stress environment in the cell that generates 8-
oxo-dGTP thereby stimulating T>G mutations in a C[T>G]T
context. In line with this, 5-FU treatment is less cytotoxic when
combined with antioxidants52 and ROS production is directly
correlated with 5-FU treatment53,54.
An alternative explanation of the underlying mutational pro-
cess of COSMIC Signature 17 observed in 5-FU treated patients
can be attributed to an imbalance of the nucleotide pool by TYMS
inhibition, which is considered to be the major drug target of 5-
FU. The 5-FU metabolite 5-FdUMP hampers the synthesis of
dTMP which results in a depletion of dTTPs in the nucleotide
pool55,56 and impaired dTMP biosynthesis results in accelerated
rates of genomic deoxyuridine triphosphate (dUTP)
incorporation57,58. Next to dUTPs, also the 5-FU related bypro-
duct 5-FdUTP can be incorporated during replication, which
results in the accumulation of U:A and 5-FU:A base pairs56.
These mutation types largely recapitulate Signature 17 and for
this reason nucleotide imbalance by TYMS inhibition is a plau-
sible cause for the here observed 5-FU mutations as well,
although the strong similarity with the process active in eso-
phageal cancer is not easily explained. In any case, further
experimental follow-up will be required to dissect the underlying
molecular mechanisms and to conclude whether one mutational
mechanism is responsible for 5-FU speciﬁc mutation accumula-
tion or that the 5-FU signature is the result of multiple mutational
processes operating simultaneously on the genome (e.g., 8-oxo-
dGTP, dUTPs, and 5-FdUTPs) that are accompanied by DNA
repair mechanisms (e.g., uracil removal by uracil-DNA glycosy-
lase [UDG]). Indeed, recent work revealed that the base excision
DNA repair machinery selectively corrects Signature 17 muta-
tions depending on its position around the nucleosome59. The
involvement of DNA repair might also explain why tumors
deﬁcient in the p53 DNA damage checkpoint regulatory pathway
accumulate more 5-FU mutations. Interestingly, breast tumors
with high contribution of Signature 17 mutations were recently
shown to have poor prognosis60.
Nevertheless, we found that the mutation contribution of 5-
FU administration does not have a great impact on the total
tumor mutational burden and the driver landscape of the
cancer in the majority of the patients. However, as the
mechanisms driving 5-FU resistance remains largely to be
elucidated, it cannot be excluded that induced mutations con-
tribute to this process.
Furthermore, we calculated that young cancer survivors exhibit
an increased risk for developing chemotherapy-related second
malignancies as 5-FU can accelerate the rate of introducing novel
oncogenic mutations in normal cells. Therefore treatment deci-
sion makers must be aware of the increased risk factors of 5-FU
administration to cancer patients at a relatively young age61,62.
Here, we have shown that the administration of ﬂuoropyr-
imidines activates a mutational process that results in a highly
characteristic mutational signature and as such, contributes to the
mutational landscape of human (cancer) cells. Moreover, our
results indicate that distinct triggers or processes can be at the
origin of highly similar mutational signatures. Insights from this
study could serve as a basis for future research to elucidate when
and how these mutagenic agents converge on similar molecular
mechanisms.
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Methods
Patient cohort. We selected patients of the CPCT-02 (NCT01855477) and DRUP
(NCT02925234) clinical studies, which were approved by the medical ethical
committees (METC) of the University Medical Center Utrecht and the Netherlands
Cancer Institute, respectively. This national initiative consists of nearly 50 oncology
centers from The Netherlands and aims to improve personalized cancer. To this
end, Hartwig Medical Foundation sequences and characterizes the genomic land-
scape for a large number of patients. Furthermore, genomics data is integrated with
clinical data which consists of primary tumor type, biopsy location, gender, pre-
treatment type before biopsy, and treatment type after biopsy. A detailed description
of the consortium and the whole patient cohort has been described in detail in
Priestley et al.17. For this study, we selected cancers with primary tumor location in
the breast, colon, and esophagus. Next, we also included all sample IDs, irrespective of
the primary tumor location, which underwent at least 2 biopsies. Samples for which
pretreatment was not documented (hasSystemicPreTreatment=NA) were excluded
from this study. All used sample IDs in this study can be found in our GitHub
repository (https://github.com/UMCUGenetics/5FU/blob/master/data/invivo/
Used_Sample_IDs.txt).
Organoid culturing. A signed approval was obtained by the medical ethical
committee UMC Utrecht (METC UMCU) for using the human small intestinal
organoid line strain STE072 under STEM protocol (METC 10/402). These isogenic
healthy human small intestinal organoids were cultured as described previously15.
In short, organoids were grown on Complete Human Intestinal Organoid (CHIO)
medium, supplemented with 30% Adv+++ (Advanced DMEM F12 [Thermo-
ﬁsher], supplemented with glutamax [1%, Thermoﬁsher], hepes [10 mM, Ther-
moﬁsher], penicillin/streptomycin [1%, Thermoﬁsher]), in house produced Wnt
(50%)63 and R-spondin (20%)63, B27 supplement (1×, Thermoﬁsher), nicotina-
mide (10 mM Sigma), N-acetylcysteine (1.25 mM, Sigma), Primocin (0.1 mg/ml,
Invivogen), A83–01 (0.5 μM, Tocris Bioscience), recombinant noggin (0.1 μg/ml,
Peprotech), SB202190 (10 μM, Sigma) and hEGF (50 ng/ml, Peprotech). Organoids
were embedded in matrigel and medium was refreshed every 2–3 days. A titration
series was performed ranging from 0 to 100 uM 5-FU (0, 3.13, 6.25, 12.5, 25, 50,
and 100 uM). The selected concentration of 6.25 uM was where roughly 50% of
organoids grew out further after the 5 cycles of treatment. The selected con-
centration (i.e., 6.25 μM) is lower than often used in acute dosing experiments as
these conditions were found to kill or senescence all cells. CHIO medium con-
taining 6.25 uM 5-FU was added to the organoids 5 days post seeding, for a period
of 3 days, after which the 5-FU-containing medium was refreshed with 5-FU-free
CHIO medium for two consecutive days. The organoids were then left to rest for
2 days. This 7-day treatment cycle was repeated for 5 weeks after which the
medium was changed to standard medium again and the organoids were left to rest
for an additional day. The organoids were then dissociated into single cells by
trypsinization and plated in a limited-dilution series. This was supplemented with
CHIO medium containing ROCK inhibitor (10 μM, Abmole) and hES Cell Cloning
& Recovery Supplement (1×, Tebu-Bio). Subsequently, individual clonal organoids
were manually picked and expanded to gain enough material for WGS.
DNA isolation and WGS of organoid lines. Organoids were dissociated and DNA
was isolated using the QiaSymphony DSP DNA mini kit (Qiagen, cat. No. 937236).
Libraries were prepared using the Truseq DNA nano library prep kit (Illumina, cat.
No. 20015964). Paired-end sequencing was performed (2 × 150 bp) on the gener-
ated libraries with 30x coverage using the Illumina HiSeq Xten at the Hartwig
Medical Foundation.
Somatic mutation calling. Somatic mutation data of the CPCT and DRUP project
were kindly shared by HMF on September 1, 2018. To exclude differences in
accuracy and sensitivity from somatic calling workﬂows between in vivo and
in vitro data, we pulled the HMF somatic mutation workﬂow from https://github.
com/hartwigmedical/pipeline and installed the pipeline locally using GNU Guix
with the recipe from https://github.com/UMCUGenetics/guix-additions. Full
pipeline description is explained by Priestley et al.17, and details and settings of all
the tools can be found at their Github page. Brieﬂy, sequence reads were mapped
against human reference genome GRCh37 using Burrows-Wheeler Alignment
(BWA-MEM) v0.7.5a64. Subsequently, somatic single base substitutions (SBSs) and
small insertions and deletions (INDELS) were determined by providing the gen-
otype and tumor (or organoid for in vitro analysis) sequencing data to Strelka
v1.0.1465 with adjustments as described elsewhere17. To obtain high-quality
somatic mutations that can be attributed to 5-FU exposure in the organoid lines,
we characterized the mutations that have accumulated between the sequential
clonal expansion step. As such, we only considered somatic mutations with a
variant allele frequency between 0.3 and 0.7, as mutations that fall outside this
range were potentially induced in vitro after the clonal step.
Mutational signature analysis. De novo mutational signature extraction was
performed using the NMF package (v0.21.0) with 100 iterations18. Non-negative
matrix factorization (NMF) is an unsupervised approach that decompose high-
dimensional datasets in a reduced number of meaningful patterns. For in vivo
samples, we ran NMF on the colon and breast cancer cohort including the two
organoid lines exposed to 5-FU and six organoid lines that were cultured in
identical medium for 140–146 days. In order to characterize the optimal number of
patterns, we compared the cophenetic correlation coefﬁcient over the range of
possible signatures and assigned sixteen de novo signatures. This set of de novo
extracted signatures were compared to the COSMIC cancer mutational signatures
(http://cancer.sanger.ac.uk/cosmic/signatures), to the expanded list of mutational
signatures19, and signatures from other studies20,21 using the cosine similarity from
the Mutational Patterns R package as a measure of closeness66. We also used
Mutational Patterns to determine the absolute contributions of each de novo
obtained signature for the metastatic and primary cohorts. Brieﬂy, a vector of 96
trinucleotide context counts for each sample was ﬁtted using non-negative least
squares regression to a 96 × n (where n is the number of signatures) matrix con-
sisting of the trinucleotide context probabilities for each signature. The relative
contribution of each signature was calculated by dividing the absolute counts by the
total mutation count (i.e. tumor mutational burden) of the sample.
Paired biopsies. To test whether the number of 5-FU speciﬁc mutations was
higher in the sample biopsied after 5-FU treatment than in the sample before the
treatment, we ﬁrst determined the 96-mutation count table for each sample. Next,
we normalized the absolute mutation count for each set of paired samples per
patient using the median ratio algorithm from the Deseq2 package67. Subsequently,
we performed a linear mixed effect analysis using nlme R package68 on each
mutation type to assess the relationship between the normalized mutation count
for each mutation type and treatment. We entered all the different treatment drugs
into the model that were administered to at least 3 patients after biopsy one (5-FU,
Carboplatin, Cisplatin, Oxaliplatin, Pazopanib, Pembrolizumab and Pemetrexed),
and added random effects to correct for exposure time and dose for each treatment
drug as well as the pharmacogenetics on patient level. We repeated this analysis
using the relative mutation count of each mutation type.
Ploidy and copy number analysis. We used PURPLE17 to obtain high quality
somatic ploidy and copy number (CN) regions (https://github.com/
hartwigmedical/hmftools/tree/master/purity-ploidy-estimator). Brieﬂy, this tool
combines B-allele frequency (BAF), read depth and structural variants to estimate
the purity and CN proﬁle of a tumor sample.
Clonality. The determination of the clonality of each mutation was adopted from
Priestley et al.17. Brieﬂy, the local ploidy level of each variant was calculated by
multiplying the tumor adjusted variant allele score, obtained from PURPLE, with
the local copy number level. All variants with a score above 1 are considered as
clonal. Variants exhibiting a score lower than 1 were searched for a subclonal peak
using a kernel density estimation using a kernel bandwidth of 0.05 after plotting the
variant ploidy scores of all variants of a sample. All variants present in the peaks
below the peak of ploidy= 1 were considered as subclonal mutations. Samples
having at least 500 subclonal mutations and show an overall 5-FU signature
contribution (at least 5%) were included for the subclonal analysis.
Estimation of tumor mutational burden. The mutation rate per megabase (Mb)
of genomic DNA was calculated as the total genome-wide amount of SBSs divided
over the total amount of mappable nucleotides (ACTG) in the human reference
genome (hg19) FASTA sequence ﬁle:
TMB ¼
SBSg
 
2858674662
106
  ð1Þ
In this study, we excluded hypermutant samples (>10 mutations/Mbp), as
determined by Campbell et al.69, as hypermutant samples have an impact on both
absolute and relative mutation contribution analysis.
Detection of signiﬁcantly mutated genes. Using all SBS and INDEL variants
from protein-coding genes, we ran dNdScv51 to ﬁnd signiﬁcantly mutated genes
using all SBSs and INDELs variants from protein-coding genes. This model can test
the normalized ratio of each non-synonymous mutation type individually (mis-
sense, nonsense, and splicing) over background (synonymous) mutations whilst
correcting for sequence composition and mutational signatures. A global q-value
≤0.1 was used to identify statistically signiﬁcant driver genes. A post hoc Fisher’s
exact test was performed to evaluate whether the number of mutations of indivi-
dual genes were enriched between two cohorts.
Transcription and replication strand bias. To compare the replication and
transcription strand bias between cohorts, we selected samples with a high COS-
MIC signature 17 contribution (absolute contribution >2000 mutations and relative
contribution >25% (5-FU pretreated colon n= 41, 5-FU pretreated breast n= 9,
not 5-FU pretreated esophagus n= 34). Next, we selected all the point mutations
bearing a C[N>N]T context where N can be any nucleotide, reasoning that the
majority of the C[T>G]T mutations can be attributed 5-FU exposure in colon and
breast cancer and 5-FU independent mutational processes in esophagus cancer.
Mutation types other than C[T>G]T can thus be considered as control.
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To assess DNA replication strand, we downloaded replication sequencing
(Replic-Seq) data from Tomkova et al.29 who characterized the replication timing
proﬁles from Haradhvala70. As in Tomkova et al, we used replication strand
information of 1 Mbp regions near the left and right of each origin29. Next, we
generated a mutation count matrix 12 (6 trinucleotides × 2 strands) for each
sample with replication strand information using Mutational Patterns R package66.
After counting the number of mutations on each strand per cancer type and
mutation type, a Poisson test for strand asymmetry was performed to test for
signiﬁcance. Similarly, a mutation count matrix of 12 was generated containing
transcription strand information of all point mutations with a C[N>N]T context
that fall within a gene body. The transcribed units of all protein-coding genes are
based on Ensembl v75 (hg19) including the introns and untranslated regions. After
estimating the mutation rate on the transcribed and non-transcribed strands, also a
Poisson test for strand asymmetry was performed to test for signiﬁcance. This
package contains also functions to determine the replication timing. In brief, all
point mutations were checked whether these were located in an intermediate, early
or late replicating region. Enrichment or depletion analysis of point mutations in
these genomic regions was performed using genomic distribution functions from
Mutational Patterns R package66.
Association of point mutations with mutational patterns. We estimated which
mutational process was most likely at the origin of each point mutation as pre-
viously done in Letouzé et al.28. In doing so, we considered the mutation category
(substitution type and trinucleotide context (TNC)) and the relative contribution of
each mutational signature from each tumor sample. The likelihood of a point
mutation, with a certain 96 trinucleotide context (TNC), induced by mutation
signature X from a sample Y can be expressed as follows:
rel TNCSig xSample y ¼
abs SampleSig x  rel TNCSig xP
Sig abs TNC
Sig
sample y
ð2Þ
Where abs SampleSig x is the absolute mutation contribution of signature X for that
sample; rel TNCSig x is the mutation type probability for a given TNC of signature X
divided by the sum of the mutation type probability for that TNC of all mutation
signatures; and
P
Sig abs TNC
Sig
sample y is the sum of absolute mutation contribution of
that TNC for every signature in sample Y. Overall, the sum of rel TNCSig xSample y for
every signature of one point mutation from one sample is equal to 1. Subsequently,
the relative contribution of a mutational signature to all mutations from multiple
samples was retrieved as the cumulative rel TNCSig xSample y likelihoods of every
mutation of the whole cohort. All mutations with a score of higher than 0.5 for a
given signature were considered to be originated from that signature and were fed
into dNdSCV for selection analysis.
5-FU induced cancer driver mutation risk. We used quantitative in vivo data and
qualitative mutational characteristics to model the number of oncogenic mutations
as a function of the number of cells, in the absence of negative selection. We
applied the following formula:
Mactive Nð Þ ¼ 0:015  dp  N  μ 
X
X 2 fC;Tg
Y 2 fA;C;G;Tg
i; j 2 fA;C;G;Tg
X≠Y
PiXj!Y 
niXj!Y
L
 
ð3Þ
where Mactive is number of mutations that activate driver genes, dp is depletion in
coding sequence (CDS), µ is the mutation rate, N is number of cells, PiXj>Y is
chance on iXj > Y mutation based on the mutation spectrum, niXj>Y is the number
of positions where iXj > Y mutation result in oncogene activation and L is the
length of CDS.
We used the following parameters: 1.5% of the genome is exon coding;
Mutational depletion (likely due to repair) from the coding sequence is 0.3094464
(results obtained from Blokzijl et al.16). On average 2000 extra mutations with 5-
FU signature per year accumulate in tumors due to 5-FU treatment (data based on
this study) − 40 mutations accumulate per year in absence of 5-FU (normal in vivo
mutation spectrum, 25% ~ signature 1 & 75% signature 5—results obtained from
Blokzijl et al.16). Colon cancer originates in one of the 108 colon stem cells71.
Signature 17 mutation chance with inclusion of trinucleotide context (5-FU
pretreated) and signature 1 (25%)+ signature 5 (75%) for non 5-FU treated model;
List of validated oncogenic mutations (exists of roughly 10,000 tumor suppressor
and driver variants, obtained from Tamborero et al.30. Coding sequence length of
small intestinal cells: 22563618 bp; The average duration of a 5-FU treatment
regime is 24 weeks (12 cycles consisting of 2 weeks).
Comparison with treated naive cancer cohorts. The SBSs were called using
Varscan 2.0 and post ﬁltered with a QSS score above 30. Full description of this
cohort can be found in Schütte et al.22. Both cohorts comprise of treatment naive
cancer patients.
Statistics. Unless otherwise stated, we performed a Wilcoxon rank-sum test to
compare continuous variables (for instance the relative or absolute contribution of
mutational signatures vs. treated and not treated) and a Fisher’s exact test was used
to evaluate categorical data (treatment vs. the occurrence of a certain mutation). All
statistical tests were two-sided and considered statistically signiﬁcant when P <
0.05. R version 3.4.4 was used for the statistical analyses.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
WGS data and corresponding clinical data have been obtained from the Hartwig Medical
Foundation and provided under data request number DR-047. Both WGS and clinical
data is freely available for academic use from the Hartwig Medical Foundation through
standardized procedures and request forms can be found at https://www.
hartwigmedicalfoundation.nl. The human sequencing data of the 5-FU treated and
control organoid lines have been deposited at the European Genome-phenome Archive
(http://www.ebi.ac.uk/ega/) under accession numbers (EGAS00001003592 and
(EGAS00001002955), respectively. For the primary breast cancer cohort, we used the
publicly available somatic mutations from BASIS cohort (BRCA-EU dataset from https://
dcc.icgc.org/) which were downloaded from the ICGC data portal on August 2, 2017.
This cohort consists of 560 primary breast cancers and has previously been characterized
in detail23. Somatic mutations of 41 primary colon cancer samples were kindly shared by
Max-Planck-Institute with a signed agreement for data and sample transfer (http://www.
oncotrack.eu). All the other data supporting the ﬁndings of this study are available within
the article and its supplementary information ﬁles and from the corresponding author
upon reasonable request. A reporting summary for this article is available as a
Supplementary Information ﬁle.
Code availability
All code and ﬁltered vcf ﬁles from 5-FU treated organoid lines are freely available at
https://github.com/UMCUGenetics/5FU.
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